Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications

Vascular Pharmacology

Volumn 53, Issue 3-4, 2010, Pages 77-87

  Sodhi, Rupinder K ^a   Singh, Nirmal ^a   Jaggi, Amteshwar S ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Apoptosis; DNA repair; Necrosis; PARP inhibitors; PARP 1

Indexed keywords

1,5 DIHYROXYISOQUINOLINE; 2 (4 HYDROXYPHENYL)BENZIMIDAZOLE 4 CARBOXAMIDE DERIVATIVE; 3 AMINOBENZAMIDE; 3,4 DIHYDRO 5 [4 1 (1 PIPERIDINYL)BUTOXYL] 1(2H) ISOQUINOLINONE; 4 IODO 3 NITROBENZAMIDE; 5 HYDROXYDIHYDROISOQUINOLINONE; 5 HYDROXYISOQUINOLINONE; 5 IODO 6 AMINO 1,2 BENZOPYRONE; 5 METHYLDIHYROISOQUINOLINONE; 6 NITROSO 1,2 BENZOPYRONE,3 NITROSOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BENZOPYRANO[4,3,2 DE]ISOQUINOLINONE DERIVATIVE; GPI 6150; INO 1001; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 1064; NU 1085; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; PD 128763; PHTHALAZINE 1(2H) ONE; PICLONAMIDE; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; CELL DEATH; COLITIS; CYTOTOXICITY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; ISCHEMIA; NEOPLASM; NERVE INJURY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SHOCK; SIGNAL TRANSDUCTION; STROKE; TISSUE INJURY;

AGING; ANIMALS; APOPTOSIS; DIABETES MELLITUS; DNA REPAIR; HIV INFECTIONS; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NECROSIS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ZINC FINGERS;

EID: 77956182983     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.06.003     Document Type: Review

References (187)

1. Affar E.B., Dallaire A.K., Castonguay V., Shah R.G. Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:245-250.
2. Aguilar-Quesada R., Munoz-Gamez J.A., Martin-Oliva D., Peralta-Leal A., Quiles-Perez R., Conde C. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr. Med. Chem. 2007, 14:1179-1187.
3. Ame J.C., Spenlehauer C., de Murica G. The PARP superfamily. Bioessays 2004, 26:882-893.
4. Andrabi S.A., Dawson T.M., Dawson V.L. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann. N.Y. Acad. Sci. 2008, 1147:233-241.
5. Andreone T.L., O'Connor M., Denenberg A., Hake P.W., Zingarelli B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J. Immunol. 2003, 170:2113-2120.
6. Ariumi Y., Turelli P., Masutani M., Trono D. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type-1 integration. J. Virol. 2005, 79:2973-2978.
7. Atkinson M.A., Maclaren N.K., Riley W.J., Winter W.E., Fisk D.D., Spillar R.P. Are insulin autoantibodies markers for insulin-dependent diabetes mellitus?. Diabetes 1986, 35:894-898.
8. Audebert M., Salles B., Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 2004, 279:55117-55126.
9. Bai P., Bakondi E., Szabo E.E., Gergely P., Szabo C., Virag L. Partial protection by poly(ADP-ribose) polymerase inhibitors from nitroxyl-induced cytotoxity in thymocytes. Free Radic. Biol. Med. 2001, 31:1616-1623.
10. Banasik M., Komura H., Shimoyama M., Ueda K. Specific inhibitors of poly (ADP-ribose) synthetase and mono (ADP-ribosyl)transferase. J. Biol. Chem. 1992, 267:1569-1575.
11. Beneke S., Burkle A. Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res. 2007, 35:7456-7465.
12. Beneke S., Diefenbach J., Burkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int. J. Cancer 2004, 111:813-818.
13. Bentle M.S., Bey E.A., Dong Y., Reinicke K.E., Boothman D.A. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J. Mol. Histol. 2006, 37:203-218.
14. Bethany C.W., Grigory L.D. Poly(ADP-ribose) polymerase-1: an international molecule of mystery. DNA Repair 2008, 7:1077-1086.
15. Blander G., de Oliveira R.M., Conboy C.M., Haigis M., Guarente L. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J. Biol. Chem. 2003, 278:38966-38969.
16. Blum D., Torch S., Lambeng N., Nissou M., Benabi A.L., Sadoul R. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP, contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
17. Bolaffi J.L., Rodd G.G., Wang J., Grodsky G.M. Interrelationship of changes in islet nicotine adeninedinucleotide, insulin secretion and cell viability induced by interleukin-1 beta. Endocrinology 1994, 134:537-542.
18. Bouchard V.J., Rouleau M., Poirier G.G. PARP-1, a determinant of cell survival in response to DNA damage. Exp. Hematol. 2003, 31:446-454.
19. Bowes J., McDonald M.C., Piper J., Thiemermann C. Inhibitors of poly(ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress. Cardiovasc. Res. 1999, 41:126-134.
20. Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays 2001, 23:795-806.
21. +. FEBS J. 2005, 44:4576-4589.
22. Cepedaa V., Fuertesa Miguel A., Castillac C., Alonsoa C., Quevedob C., Sotoa José M. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Patents Anti-Cancer Drug Disc. 2006, 1:39-53.
23. Chambon P., Weille J.D., Mandel P. Nicotinamide mononulceotide activation of new DNA dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophy. Res. Commun. 1963, 11:39-43.
24. Chang W.J., Alvarez-Gonzalez R. The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly(ADPribose) polymerase 1. J. Biol. Chem. 2001, 276:47664-47670.
25. Chatterjee P.K., Cuzzocrea S., Thiemermann C. Inhibitors of poly(ADPribose)synthetase protect rat proximal tubular cells against oxidant stress. Kidney Int. 1999, 56:973-984.
26. Chen C.F., Wang D., Hwang C.P., Liu H.W., Wei J., Lee R.P. The protective effect of niacinamide on ischemia-reperfusion-induced liver injury. J. Biomed. Sci. 2001, 8:446-452.
27. Chiang S.K., Lam T.T. Post-treatment at 12 or 18hours with 3-aminobenzamide ameliorates retinal ischemia-reperfusion damage. Invest. Ophthalmol. Vis. Sci. 2000, 41:3210-3214.
28. Chiarugi A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. J. Pharmacol. 2002, 137:761-770.
29. Chiarugi A., Moskowitz M.A. Cell biology-PARP-1-a perpetrator of apoptotic cell death. Science 2002, 297:200-201.
30. Chiarugi A., Moskowitz M.A. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J. Neurochem. 2003, 85:306-317.
31. Chung H.Y., Sung B., Jung K.J., Zou Y., Yu B.P. The molecular inflammatory process in aging. Antioxid. Redox Signal. 2006, 8:572-581.
32. Clark J.B., Ferris J.M., Pinder S. Control of nucleic acid and nicotinamide nucleotide synthesis in generating rat liver. Bichem. Biophys. Acta 1971, 238:82-87.
33. Cohen A., Leonid V., Ayelet K., David L., Abraham J., Susswein R. Long-term memory requires polyADP-ribosylation. Science 2004, 304:1820-1822.
34. Cole G.A., Bauer G., Kirsten E., Mendeleyev J., Bauer P.I., Buki K.G. Inhibition of HIV-1 IIIb replication in AA-2 and MT-2 cells in culture by two ligands of poly(ADP-ribose) polymerase: 6-amino-1, 2-benzopyrone and 5-iodo-6-amino-1, 2-benzopyrone. Biochem. Biophys. Res. Commun. 1991, 180:504-514.
35. Cosi C. New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets. Expert Opin. Ther. Patents 2002, 12:1047-1071.
36. Csiszar A., Wang M., Lakatta E.G., Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J. Appl. Physiol. 2008, 105:1333-1341.
37. Csonka C., Csont T., Onody A., Ferdinand P. Preconditioning decreases ischemia/reperfusion-induced peroxynitrite formation. Biochem. Biophys. Res. Commun. 2001, 285:1217-1219.
38. Curtin N.J. PARP inhibitors for cancer therapy. Expert Rev. Mol. Med. 2005, 15(7):1-20.
39. Cuzzocrea S., Zingarelli B., Costantino G., Szabo A., Salzman A.L., Caputi A. Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br. J. Pharmacol. 1997, 121:1065-1074.
40. Cuzzocrea S., Caputi A.P., Zingarelli B. Peroxynitrite-mediated DNA strand breakage activates poly(ADP-ribose) synthetase and causes cellular energy depletion in carrageenan-induced pleurisy. Immunology 1998, 93:96-101.
41. D'Amours D., Sallmann F.R., Dixit V.M., Poirier G.G. Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases, implications for apoptosis. J. Cell Sci. 2001, 114:3771-3778.
42. Dantzer F., Amé J.C., Schreiber V., Nakamura J., Méni.ssier-de Murcia J., de Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Meth. Enzymol. 2006, 409:493-510.
43. David K.K., Andrabi S.A., Dawson T.M., Dawson V.L. Parthanatos, a messenger of death. Front. Biosci. 2009, 1(14):1116-1128.
44. De la Lastra C.A., Villegas I., Sanchez S. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr. Pharm. Des. 2007, 13:933-962.
45. De Murcia G., Menissier de Murcia J. Poly(ADP-ribose) polymerase, a molecular nick-sensor. Trends Biochem. Sci. 1994, 19:172-176.
46. De Murcia J.M., Niedergang C., Trucco C., Ricou M., Dutrillaux B., Mark M., Oliver F.J., Masson M., Dierich A., Le Meur M., Walztinger C., Chambon P. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:7303-7307.
47. Delaney C.A., Green M.H., Lowe J.E., Green I.C. Endogenous nitric oxide induced by interleukin-1 beta in rat islets of Langerhans and HIT-T15 cells causes significant DNA damage as measured by the "comet" assay. FEBS Lett. 1993, 333:291-295.
48. Docherty J.C., Kuzio B., Silvester J.A., Bowes J., Thiemermann C. An inhibitor of poly(ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Br. J. Pharmacol. 1999, 127:1518-1524.
49. Eltze T., Boer R., Wagner T., Weinbrenner S., McDonald M.C., Thiemermann C., Bürkle A., Klein T. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol. Pharmacol. 2008, 74:1587-1598.
50. Faro R., Toyoda Y., McCully J., Jagtap P., Szabo E., Virag L. Protective effect on regional myocardial function and infarct size induced by PJ34, a novel poly(ADP-ribose) synthetase inhibitor. Ann. Thorac. Surg. 2002, 73:575-581.
51. Ferrante R.J., Hantraye P., Brouillet E., Beal M.F. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. 1999, 823:177-182.
52. Fidalgo S.S., Villegas I., Martín A., Hidalgo M.S., de la Lastra M.S. PARP inhibition reduces acute colonic inflammation in rats. Eur. J. Pharmacol. 2007, 563:216-223.
53. Fukuzawa M., Satoh J., Muto G., Muto Y., Nishimura S., Miyaguchi S., Qiang X.L., Toyota T. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol. Lett. 1997, 59:7-11.
54. Furlini G., Re M.C., La Placa M. Increased poly(ADP-ribose) polymerase activity in cells infected by human immunodeficiency virus type-1. Microbiologica 1991, 14:141-148.
55. Gagne J.P., Hendzel M.J., Driot A., Poririer G.G. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr. Opin. Cell Bio. 2006, 18:145-151.
56. Garchon H.J., Levi-Strauss M. Unexpected sensitivity of non-obese diabetic mice with a disrupted poly(ADP-ribose) polymerase-1 gene to streptozotocin induced and spontaneous diabetes. Diabetes 2002, 51:1470-1476.
57. Gerö D., Szabó C. Poly(ADP-ribose) polymerase: a new therapeutic target? 2008.
58. Geske F.J., Gerschenson L.E. The biology of apoptosis. Hum. Pathol. 2001, 32:1029-1038.
59. Giovannelli L., Cozzi A., Guarnieri I., Dolara P., Moroni F. Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors. J. Cereb. Blood Flow Metab. 2002, 22:697-704.
60. Goto S., Xue R., Sugo N., Sawada M., Blizzard K.K., Poitras M.F. Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke 2002, 33:1101-1106.
61. Grupp I.L., Jackson T.M., Hake P., Grupp G., Szabo C. Protection against hypoxia-reoxygenation in the absence of poly(ADP-ribose) synthetase in isolated working hearts. J. Mol. Cell Cardiol. 1999, 31:297-303.
62. Ha H.C., Juluri K., Zhou Y., Leung S., Hermankova M., Snyder S.H. Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration. Proc. Nat. Acad. Sci. 2001, 98:3364-3368.
63. Haddad M., Rhinn H., Bloquel C., Coqueran B., Szabó C., Plotkine M. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br. J. Pharmacol. 2006, 149:23-30.
64. Haince J.F., Rouleau M., Hendzel M.J., Masson J.Y., Poirier G.G. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med. 2005, 11:456-463.
65. Halmosi R., Berente Z., Osz E., Toth K., Literati-Nagy P., Sumegi B. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol. Pharmacol. 2001, 59:1497-1505.
66. Hamby A.M., Suh S.W., Kauppinen T.M., Swanson R.A. Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after ischemia-reperfusion. Stroke 2007, 38:632-636.
67. Haskó G., Mabley J.G., Németh Z.H., Pacher P., Deitch E.A., Szabó C. Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. Mol. Med. 2002, 8:283-289.
68. Hassa P.O. The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival. Front. Biosci. 2009, 1(14):72-111.
69. Hassa P.O., Covic M., Hasan S., Imhof R., Hottiger M.O. The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J. Biol. Chem. 2001, 276:45588-45597.
70. Heller B., Wang Z.Q., Wagner E.F., Radons J., Burkle A., Fehsel K. Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J. Biol. Chem. 1995, 270:11176-11180.
71. Hergartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
72. Infante J., Sánchez-Juan P., Mateo I., Rodríguez-Rodríguez E., Sánchez-Quintana C., Llorca J. Poly(ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease. J. Neurol. Sci. 2007, 15:68-70.
73. Iwashita A., Yamazaki S., Mihara K., Hattori K., Yamamoto H., Ishida J. Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2004, 309:1067-1078.
74. Jagtap P., Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitiors. Nat. Rev. Drug Discov. 2005, 4:421-440.
75. Jagtap P., Soriano F.G., Virag L., Liaudet L., Mabley J., Szabo E. Novel phenanthridinone inhibitors of poly- (ADP-ribose) synthetase, potent cytoprotective and anti-shock agents. Crit. Care Med. 2002, 30:1071-1082.
76. Jagtap P., Soriano F.G., Virag L., Liaudet L., Mabley J., Szabo E., Hasko G., Marton A., Lorigados C.B., Gallyas F. Novel phenanthridinone inhibitors of poly-(ADP-ribose) synthetase: potent cytoprotective and anti-shock agents. Crit. Care Med. 2002, 30:1071-1082.
77. Jung J.S., Park M.Y., Lee R.H., Jun J.S., Kim Y.K. Protection against hydrogen peroxide induced injury in renal proximal tubule cell lines by inhibition of poly-(ADP-ribose) synthase. Kidney Blood Press Res. 2000, 23:14-19.
78. Kameoka M., Tanaka Y., Ota K., Itaya A., Yamamoto K., Yoshihara K. HIV-1 Tat protein is poly(ADP-ribosyl)ated in vitro. Biochem. Biophys. Res. Commun. 1999, 261:90-94.
79. Kameoka M., Nukuzuma S., Itaya A., Tanaka Y., Ota K., Ikuta K., Yoshihara K. RNA interference directed against poly(ADP-ribose) polymerase-1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J. Virol. 2004, 78:8931-8934.
80. Kameoka M., Nukuzuma S., Itaya A., Ota K., Tanaka Y., Ikuta K. Poly(ADP-ribose) polymerase-1 is required for the interaction of HIV type-1 genome near centromeric alphoid DNA in human and murine cells. Biochem. Biophys. Res. Commun. 2005, 334:412-417.
81. Kameoka M., Nukuzuma S., Itaya A., Tanaka Y., Ota K., Inada Y. Poly(ADP-ribose)polymerase-1 is required for integration of the human immunodeficiency virus type 1 genome near centromeric alphoid DNA in human and murine cells. Biochem. Biophys. Res. Commun. 2005, 334:412-417.
82. Kauppinen T.M. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease. Neurochem. Int. 2007, 50:954-958.
83. Kauppinen T.M., Swanson R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 2007, 145:1267-1272.
84. Kauppinen T.M., Suh S.W., Berman A.E., Hamby A.M., Swanson R.A. Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J. Cereb. Blood Flow Metab. 2009, 29:820-829.
85. Keil C., Gröbe T., Oei S. L. MNNG-induced cell death is controlled by interactions between PARP-1, poly(ADP-ribose) glycohydrolase, and XRCC1. J. Biol. Chem. 2006, 281:34394-34405.
86. + dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004, 119:803-814.
87. + into a nuclear signal. Genes Dev. 2005, 19:1951-1967.
88. Koh D.W., Dawson T.M., Dawson V.L. Poly(ADP-ribosyl)ation regulation of life and death in nervous system. Cell Mol. Life Sci. 2005, 62:760-768.
89. Krasil'nikov I.I., Kalnina L.B., Korneeva N., Nosik D.N., Zlobin A.I. Inhibitors of ADP ribosylation as antiviral agents, an experimental study in a model of HIV infection. Vopr. Virusol. 1999, 36:216-218.
90. Kraus W., Lis J. PARP goes transcription. Cell 2003, 113:677-683.
91. Kun E., Kirsten E., Ordahl C.P. Coenzymatic activity of randomly broken or intact double-stranded DNAs in auto and histone H1 trans-poly(ADP-ribosylation), catalyzed by poly(ADP-ribose) polymerase (PARP I). J. Biol. Chem. 2002, 277:39066-39069.
92. , histones H1 and H3, and ATP. Biochemistry 2004, 43:210-216.
93. Kurosaki T., Ushiro H., Mitsuuchi Y., Suzuki S., Matsuda M., Matsuda Y., Katunuma N., Kangawa K., Matsuo H., Hirose T., Inayama S., Shizuta Y. Primary structure of human poly(ADP-ribose) synthetase as deduced from cDNA sequence. J. Biol. Chem. 1987, 262(33):15990-15997.
94. La Placa M.C., Zhang J., Raghupathi R., Li J.H., Smith F., Bareyre F.M. Pharmacologic inhibition of poly(ADP-ribose)polymerase is neuroprotective following traumatic brain injury in rats. J. Neurotrauma 2001, 18:369-376.
95. Lewis C., Low J.A. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Curr. Opin. Invest. Drugs 2007, 8:1051-1056.
96. Li J.H., Zhang J. PARP inhibitors. Idrugs 2001, 4:804-812.
97. Li F., Szabó C., Pacher P., Southan G.J., Abatan O.I., Charniauskaya T., Stevens M.J., Obrosova I.G. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 2004, 47(4):710-717.
98. Liaudet L., Szabo A., Soriano F.G., Zingarelli B., Szabo C., Salzman A.L. Poly(ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia. Shock 2000, 14:134-141.
99. Liaudet L., Szabo E., Timashpolsky L., Virag L., Cziraki A., Szabo C. Suppression of poly(ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction, long-term morphological and functional consequences. Br. J. Pharmacol. 2001, 133:1424-1430.
100. Lindahl T., Satoh M.S., Poirier G.G., Klungland F. A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci. 1995, 20:405-411.
101. Lo E.H., Bosque-Hamilton P., Meng W. Inhibition of poly(ADP-ribose) polymerase, reduction of ischemic injury and attenuation of N-methyl-d-aspartate-induced neurotransmitter dysregulation. Stroke 1998, 29:830-836.
102. Mabley J.G., Jagtap P., Perretti M., Getting S.J., Salzman A.L., Virág L., Szabó E., Soriano F.G., Liaudet L., Abdelkarim G.E., Haskó G., Marton A., Southan GJ., Szabó C. Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm. Res. 2001, 50:561-569.
103. Malanga M., Althaus F.R. Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. J. Biol. Chem. 2004, 27:5244-5248.
104. Mandir A.S., Simbulan-Rosenthal C.M., Poitras M.F., Lumpkin J.R., Dawson V.L., Smulson M.E. A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. J. Neurochem. 2002, 831:186-192.
105. Martin D.R., Lewington A.J., Hammerman M.R., Padanilam B.J. Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279:R1834-R1840.
106. Masiello P., Novelli M., Fierabracci V., Bergamini E. Protection by 3-aminobenzamide and nicotinamide against streptozotocin-induced beta-cell toxicity in vivo and in vitro. Res. Commun. Chem. Pathol. Pharmacol. 1990, 69:17-32.
107. Masson M., Niedergang C., Schreiber V., Muller S., Menissier-de Murcia J., de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell Biol. 1998, 18:3563-3571.
108. Masutani M., Suzuki H., Kamada N., Watanabe M., Ueda O., Nozaki T.K., Jishage T., Watanabe T., Sugimoto H., Nakagama T., Ochiya T., Sugimura T. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:2301-2304.
109. Masutani M., Nozaki T., Nakamoto K., Nakagama H., Suzuki H., Kusuoka O., Tsutsumi M., Sugimura T. The response of Parp knockout mice against DNA damaging agents. Mutat. Res. 2000, 462:159-166.
110. Matthias A., Michael O.H. Poly(ADP-ribose) polymerase-1 at the crossroad of metabolic stress and inflammation in aging. Aging 2009, 1:458-468.
111. Mazzon E., Serraino I., Li J.H., Dugo L., Caputi A.P., Zhang J. GPI- 6150, a poly(ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation. Eur. J. Pharmacol. 2001, 415:85-94.
112. Mazzon E., Genovese T., Di Paola R., Muià C., Crisafulli C., Malleo G. Effects of 3-aminobenzamide, an inhibitor of poly ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. Eur. J. Pharmacol. 2006, 549:149-156.
113. McDonald M.C., Mota-Filipe H., Wright J.A., Abdelrahman M., Threadgill M.D., Thompson A.S. Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br. J. Pharmacol. 2001, 130:843-850.
114. Meyer-Ficca M.L., Meyer R.G., Jacobson E.L., Jacobson M.K. Poly(ADP-ribose) polymerases: managing genome stability. Int. J. Biochem. Cell. Biol. 2005, 37:920-926.
115. Moroni F., Meli E., Peruginelli F., Chiarugi A., Cozzi A., Picca R. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ. 2001, 8:921-932.
116. Murcia J.M. A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis and sister chromatid exchange following DNA damage. Proc. Nat. Acad. Sci. U.S.A. 1995, 92:4753-4757.
117. Murphy M.P., Partridge L. Toward a control theory analysis of aging. Annu. Rev. Biochem. 2008, 77:777-798.
118. Mustapha O., Datta R., Oumouna-Benachour K., Suzuk Y., Hans C., Matthews K. Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J. Immunol. 2006, 177:6489-6496.
119. Nagele A. Poly(ADP-ribosyl)ation as a fail-safe, transcription-independent, suicide mechanism in acutely DNA-damaged cells, a hypothesis. Radiat. Environ. Biophys. 1995, 34:251-254.
120. Nguewa P.A., Fuertes M.A., Valladares B., Alonso C., Pérez J.M. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog. Biophys. Mol. Biol. 2005, 881:43-72.
121. Nguewa P.A., Fuertes M.A., Cepeda V., Alonso C., Quevedo C., Soto M. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med. Chem. 2006, 21:47-53.
122. Oei S.L., Shi Y. Transcription factor Yin Yang 1 stimulates poly(ADP-ribosyl)ation and DNA repair. Biochem. Biophys. Res. Commun. 2001, 284:450-454.
123. Oei S.L., Keil C., Ziegler M. Poly(ADP-ribosylation) and genomic stability. Biochem. Cell Biol. 2005, 83:263-269.
124. +-induced cytotoxicity in Parkinson's disease in vitro models. Biochem. Biophys. Res. Commun. 2007, 357:3596-3602.
125. Pal P., Szabo C. Role of Poly(ADP-ribose)polymerase 1(PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 2007, 25:235-260.
126. Peralta-Leal A., Rodríguez-Vargas J.M., Aguilar-Quesada R., Rodríguez M.I., Linares J.L., de Almodóvar M.R., Oliver F.J. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radical Biol. Med. 2009, 47(1):13-26.
127. Pieper A.A., Brat D.J., Krug D.K., Watkins C.C., Gupta A., Blackshaw S. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:3059-3064.
128. Pieper A.A., Walles T., Wei G., Clements E.E., Verma A., Snyder S. Myocardial postischemic injury is reduced by poly(ADPribose) polymerase-1 gene disruption. Mol. Med. 2000, 6:271-282.
129. Plummer E.R. Inhibition of poly(ADP-ribose) in cancer. Curr. Opin. Pharmacol. 2006, 6:364-368.
130. Poitras M.F., Koh D.W., Yu S.W., Andrabi S.A., Mandir A.S., Poirier G.G. Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. Neuroscience 2007, 148:198-211.
131. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 1998, 13:35-38.
132. Rapizzi E., Fossati S., Moroni F., Chiarugi A. Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes. Mol. Pharmacol. 2004, 66:890-898.
133. Ratnam K., Low J.A. Current development of clinical inhibitors poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 2007, 13:1383-1388.
134. Robert S.B., Vagni V.A., Nathaniel P.D., Jenkins L.W., Dixon C.E., Szabo C. Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J. Neurotrauma 2007, 24:1399-1405.
135. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10(4):293-301.
136. Samper E., Goytisolo F.A., Menissier de Murcia J., Gonzalez-Suarez E., Cigudosa J.C. Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability. J. Cell Biol. 2001, 154:49-60.
137. Sandler S., Welsh M., Anderson A. Streptozotocin-induced impairment of islet B-cell metabolism and its prevention by a hydroxyl radical scavenger and inhibitors of poly(ADP-ribose) synthetase. Acta Pharmacol. Toxicol. Copenhagen 1983, 53:392-400.
138. Sarkar D., Fisher P.B. Molecular mechanisms of aging-associated inflammation. Cancer Lett. 2006, 236:13-23.
139. Saunders L.R., Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007, 26:5489-5504.
140. Saxena A., Saffery R., Wong L.H., Kalitsis P., Choo K.H. Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated. J. Biol. Chem. 2002, 277:26921-26926.
141. Schreiber V., Danter F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
142. Scott G.S., Jakeman L.B., Stokes B.T., Szabo C. Peroxynitrite production and activation of poly(adenosine diphosphate-ribose) synthetase in spinal cord injury. Ann. Neurol. 1999, 45:120-124.
143. Scott G.S., Kean R.B., Mikheeva T., Fabis M.J., Mabley J.G., Szabó C. The therapeutic effects of PJ34 N-(6-oxo-5, 6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 2004, 310:1053-1061.
144. Shall S., de Murcia G. Poly(ADP-ribose) polymerase-1, what have we learned from the deficient mouse model?. Mutat. Res. 2000, 460:1-15.
145. Simbulan-Rosenthal C.M., Rosenthal D.S., Konopka G., Luo R., Wang Z.Q., Schultz P. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:11274-11279.
146. Smith S. The world according to PARP. Trends Biochem. Sci. 2001, 26:174-179.
147. Smulson M.E., Simbulan-Rosenthal C.M., Boulares A.H., Yakovlev A., Stoica B., Iyer S. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of P53 and E2F-1. Adv. Enzyme. Regul. 2000, 40:183-215.
148. Sodhi R.K., Singh M., Singh N., Jaggi A.S. Protective effects of caspase-9 and poly(ADP-ribose) polymerase inhibitors on ischemia-reperfusion-induced myocardial injury. Arch. Pharm. Res. 2009, 32:1037-1043.
149. Sohal R.S., Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996, 273:59-63.
150. Soós J., Engelhardt J.I., Siklós L., Havas L., Majtényi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport 2004, 11:715-718.
151. Soriano F.G., Pacher P., Mabley J., Liaudet L., Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADPribose) polymerase. Circ. Res. 2001, 89:684-691.
152. Soriano F.G., Virag L., Jagtap P., Szabo E., Mabley J.G., Liaudet L., Marton A., Hoyt D.G., Murthy K.G., Salzman A.L. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 2001, 7:108-113.
153. Soriano F.G., Liaudet L., Szabo E., Virag L., Mabley J., Pacher P., Szabo C. Resistance against acute septic peritonitis in poly(ADP-ribose) polymerase deficient mice. Shock 2002, 17:286-292.
154. Southan G.J., Szabo C. Poly(ADP-ribose)polymerase inhibitors. Curr. Med. Chem. 2003, 10:321-340.
155. Stevens M.J., Li F., Drel V.R., Abatan O.I., Kim H., Burnett D., Larkin D., Obrosova I.G. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J. Pharmacol. Exp. Ther. 2007, 320:458-464.
156. Stone D.H., Albadawi H., Conrad M.F., Entabi F., Stoner M.C., Casey P.J., Cambria R.P., Watkins M.T. PJ34, a poly-ADP-ribose polymerase inhibitor, modulates visceral mitochondrial activity and CD14 expression following thoracic aortic ischemia-reperfusion. Am. J. Surg. 2009, 198:250-255.
157. Sung Y.J., Ambron R.T. Poly(ADP-ribose) polymerase-1(PARP-1) and evolution of learning and memory. Bioessays 2004, 26:1268-1271.
158. Suto M.J., Turner W.R., Werbel L.M., Sebolt J.S. Dihyrdroisoquinolinones; the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase. Anticancer Drug Dev. 1991, 6:107-117.
159. Szabados E., Fischer G.M., Gallyas F.J., Kispal G., Sumegi B. Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart. Free Radical Biol. Med. 2000, 27:1103-1113.
160. Szabo C. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions. Curr. Vasc. Pharmacol. 2005, 3:301-303.
161. Szabo C., Lim L.H., Cuzzocrea S., Getting S.J., Zingarelli B., Flower R.J. Inhibition of poly(ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J. Exp. Med. 1997, 186:1041-1049.
162. Szabo E., Virag L., Bakondi E., Gyure L., Hasko G., Bai P. Peroxynitrite production, DNA breakage and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J. Invest. Dermatol. 2001, 117:74-80.
163. Szabo C., Pacher P., Swanson R.A. Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol. Sci. 2006, 27:626-630.
164. Szabó C., Biser A., Benko R., Böttinger E., Suszták K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 2006, 55:3004-3012.
165. Tabuchi K., Ito Z., Tsuji S., Nakagawa A., Serizawa F., Hara A. Poly(adenosine diphosphate-ribose) synthetase inhibitor 3-aminobenzamide alleviates cochlear dysfunction induced by transient ischemia. Ann. Otol. Rhinol. Laryngol. 2001, 110:118-121.
166. Takahashi K., Pieper A.A., Croul S.E., Zhang J., Snyder S.H., Greenberg J.H. Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res. 1999, 829:46-54.
167. Thiemermann C., Bowes J., Myint F., Vane J.R. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:679-683.
168. Ullrich O., Diestel A., Eyupoglu I.Y., Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat. Cell. Biol. 2001, 3:1035-1042.
169. Unlu E.S., Koc A. Effects of deleting mitochondrial antioxidant genes on life span. Ann. N.Y. Acad. Sci. 2007, 1100:505-509.
170. Vaziri H., West M.D., Allsopp R.C., Davison T.S., Wu Y.S., Arrowsmith C.H., Poirier G.G., Benchimol S. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 1997, 16:6018-6033.
171. Vidal J., Fernandez-Balsells M., Sesmilo G., Aguilera E., Casamitjana R., Gomis Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diab. Care 2000, 23:360-364.
172. Virág L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr. Vasc. Pharmacol. 2005, 3:209-214.
173. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54:375-429.
174. Virág L., Salzman A.L., Szabó C. Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J. Immunol. 1998, 161:3753-3759.
175. Virág L., Bai P., Bak I., Pacher P., Mabley J.G., Liaudet L. Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med. Sci. Monit. 2004, 10. BR77-83.
176. Wang Z.Q., Auer B., Stingl L., Berghammer H., Haidacher D., Schweiger M. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995, 9:509-520.
177. Wang Y., Dawson V., Dawson T.M. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 2009, 218(2):193-202.
178. 2 but not apoptosis. Gastroenterology 1995, 109:472-482.
179. Watson C.Y., Whish W.J., Threadgill M.D. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bio. Org. Med. Chem. 1998, 6:721-734.
180. Wayman N., McDonald M.C., Thompson A.S., Threadgill M.D., Thiemermann C. 5-Aminoisoquinolinone, a potent inhibitor of poly(adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur. J. Pharmacol. 2001, 430:93-100.
181. Wilson G.L., Hartig P.C., Patton N.J., Le Doux S.P. Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly(ADP-ribose) synthetase and cellular distribution. Diabetes 1988, 37:213-216.
182. Yamagoe S., Kohda T., Oishi M. Poly(ADP-ribose) polymerase inhibitors suppress UV-induced human immunodeficiency virus type 1 gene expression at the posttranscriptional level. Mol. Cell Biol. 1991, 11:3522-3527.
183. Yang Z., Zingarelli B., Szabo C. Effect of genetic disruption of poly(ADPribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 2000, 13:60-66.
184. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff J. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297:259-263.
185. Zaremba T., Curtin N.J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 2007, 7:515-523.
186. Zhang J., Pieper A., Snyder S.H. Poly(ADP-ribose) synthetase activation, an early indicator of neurotoxic DNA damage. J. Neurochem. 1995, 65:1411-1414.
187. Zingarelli B., Hake P.W., O'Connor M., Denenberg A., Wong H.R., Kong S. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1408-H1415.